Materials Science Capabilities
Implementation of an established approach, using technologies to fully characterise both molecular level properties and bulk properties, can be applied either predictively, for optimisation purposes or for inclusion in regulatory documentation. These technologies can be applied during clinical development or to materials already in the market place. With respect to drug substance, close collaboration between CMC and API teams will ensure determination of the most appropriate form for pharmaceutical application, offering a long term view to successful project progression. Similarly, characterisation of excipients, or drug – excipient interactions, either throughout the recommended manufacturing process or in the final product, can be employed to ensure robust performance.
SMi Highly Potent Active Pharmaceutical IngredientsThe SMi Highly Potent Active Pharmaceutical Ingredients Conference will be attended by Mark Anstiss, Scale-up Chemist.
SMi Highly Potent Active Pharmaceutical IngredientsDates: 21st - 22nd MayLocation: Birmingham, UK
66th Annual ASMS ConferenceThe 66th ASMS Conference on Mass Spectrometry and Allied Topics Conference will be attended by Michael Blackburn, Method Development Scientist (Physiochemical). Michael will also be presenting during the conference, at the Proteins & Peptides Waters Users Meeting, with a presentation entitled; A Powerful Hybrid IA-LC-MS/MS Method Quantification of Insulin Analogues and
66th Annual ASMS ConferenceDates: 3rd - 7th JuneLocation: San Diego, US
2018 BIO International ConventionThe 2018 BIO International Convention will be attended by Mark Chadwick, Head of Business Development.
2018 BIO International ConventionDates: 4th - 7th JuneLocation: Boston, USA